New use of angiotensin ii type 2 receptor agonist

an angiotensin ii type 2 receptor, new technology, applied in the direction of amide active ingredients, organic active ingredients, peptide/protein ingredients, etc., can solve the problems of severe illness, morbidity and/or death, unwell or fatigued patients, etc., to achieve less side effects, less toxic, and more effective

Active Publication Date: 2021-09-23
VICORE PHARMA AB
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The immune response can often lead a patient feeling unwell or fatigued.
If a patient's immune system is compromised, or not effective enough to prevent the spread of a virus, this can lead to severe illness and, in some instances, morbidity and / or death.
Indeed, there are many different types of viruses that can seriously affect lung function and cause respiratory illnesses.
Moreover, C21 has been found not to improve pulmonary gas exchange or have other relevant beneficial clinical effects in a model of acute lung injury (Menk et al, J. Inflamm. Res., 11, 169 (2018)).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 2

In Vitro Cell Assay I

[0105]SARS virus cellular entry and / or replication is studied in vitro using appropriate methods described in the scientific literature, for example as described in Struck et al, Antioviral Research, 94, 288 (2012), Walls et al, Cell, 180, 1 (2020) and / or Zhou et al, Nature, 579, 270 (2020). Other relevant / equivalent cell types (including alveolar epithelial type II (ATII) cells) and methods for measuring viral cellular entry and / or replication may also be used. Prior to and / or during exposure of cells to different amounts of virus, the cells are incubated with different concentration (e.g. from 0.1 nM to 1 mM) of C21 for different periods of time.

example 3

In Vitro Cell Assay II

[0106]Experiments are performed by FibroFind Limited, Gateshead, United Kingdom.

[0107]Precision Cut Lung Slices (PCLuS) from explanted diseased (with idiopathic pulmonary fibrosis) human lung tissue are used. PCLuS are prepared from explanted human lung tissue collected at the time of lung transplantation. PCLuS are rested for 48 hours to allow the post-slicing stress period to elapse before experiments begin. PCLuS are cultured in the presence or absence of Alk5 inhibitor (10 μM) as a positive control. In addition, in separate wells, PCLuS are cultured in the presence of C21 at different concentrations (0.01, 0.1, 1 and / or 10 μM).

[0108]PCLuS culture supernatant (n=4-6 per group) is collected daily and snap frozen for quantification of levels of epithelial cell damage biomarkers (MMP7, GDF15, CA125, CEA, CA19-9, cytokeratin 18 and / or CYFRA-21-1) at 48, 96 and 144 hours using R&D Duoset ELISA kits and / or sandwich ELISA (from e.g. Abcam and / or RayBioTech).

example 4

[0109]Clinical Trial Evaluating Safety and Efficacy of C21 in Patients with SARS-CoV-2 Virus Infection (I)

[0110]This is a clinical study evaluating the safety and effectiveness of C21 (100-400 mg, including 200 mg, daily).

[0111]The key objectives / endpoints of the study are to evaluate the safety and efficacy of C21 in participants with infection with SARS-CoV-2 virus.

[0112]Evaluation of efficacy of C21 is determined by determining inter alia:[0113]improvement in signs, symptoms, quality of life, manifestations and / or complications related to the disease, including fever, pulmonary and / or cardiac function, blood oxygen tension / hypoxia, cough, shortness of breath, multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), secondary pneumonia by other microorganisms and / or patient and / or clinician reported quality of life (QoL) outcome measures;[0114]duration of hospital stay;[0115]need for invasive and / or non-invasive ventilation;[0116]surrogate markers of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and / or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and / or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

Description

[0001]This application claims the priority benefit of GB 2004209.9, filed Mar. 23, 2020, and GB 2009574.1, filed Jun. 23, 2020.FIELD OF THE INVENTION[0002]This invention relates to the new use of a known compound.BACKGROUND AND PRIOR ART[0003]A virus is a very small organism comprising genetic material (DNA or RNA) that is capable of infecting a biological organism. A virus invades and attaches itself to a living cell, after which it multiplies to produce more virus particles (virions), which attach to and enter susceptible cells.[0004]A virus may either kill a cell or alter its functions leading to the infection of other cells. This will then generally lead to what is termed as a viral disease (or a viral infection).[0005]In general, viruses only infect one type of cell, but can be transmitted in various ways, including contact with infected individuals or their bodily secretions, animals (such as arthropods), or inanimate objects. Viruses can also be transmitted by inhalation or s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4178A61K45/06A61K31/573A61K38/21A61K31/706A61K31/16A61K31/7056A61K31/513A61P31/14
CPCA61K31/4178A61K45/06A61K31/573A61K38/215A61P31/14A61K31/16A61K31/7056A61K31/513A61K31/706A61K2300/00
Inventor DALSGAARD, CARL-JOHANRAUD, JOHANBATTA, ROHIT
Owner VICORE PHARMA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap